Gilder Gagnon Howe & Co’s Unity Biotechnology UBX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,860	Closed	-$151K	–	295
2019 Q1	$151K	Sell	1,860 -136	-7%	-$15.4K	﹤0.01%	254
2018 Q4	$325K	Sell	1,996 -4	-0.2%	-$531	﹤0.01%	232
2018 Q3	$326K	Hold	2,000	–	–	﹤0.01%	251
2018 Q2	$301K	Buy	+2,000	New	+$292K	﹤0.01%	244

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Gilder Gagnon Howe & Co's UBX Position: Q2 2019 in Review

Gilder Gagnon Howe & Co sold out of Unity Biotechnology (UBX) in Q2 2019, closing a stake of 1,860 shares — an estimated $151K sold.

Gilder Gagnon Howe & Co first reported a position in UBX in Q2 2018 and held it in 4 quarters. The position peaked at $326K in Q3 2018. 58 funds tracked by Wall St. Rank hold UBX as of Q2 2019.

Gilder Gagnon Howe & Co reported no remaining Unity Biotechnology position as of Q2 2019 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 1,860 Unity Biotechnology shares in Q2 2019, an estimated $151K.
Gilder Gagnon Howe & Co first reported a position in Unity Biotechnology in Q2 2018 and held it in 4 quarters.
Gilder Gagnon Howe & Co's Unity Biotechnology position peaked at $326K in Q3 2018.
58 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2019.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2019, filed 13 Aug 2019.